Company intelligence / Profile preview

Otter Pharmaceuticals

Lake Forest, Illinois, United States

Ownership: Private
Development stage: Other

Overview

Otter Pharmaceuticals, a subsidiary of Assertio Holdings, markets approved pharmaceutical products, most notably clobazam (targeting the GABAA receptor) for Lennox-Gastaut syndrome and methotrexate (targeting DHFR) for autoimmune indications such as psoriasis. Clobazam is commercialized as Sympazan® oral film for adjunctive treatment of seizures in LGS; methotrexate is provided via the OTREXUP device for subcutaneous delivery in conditions including psoriasis. Both products are approved and sold in multiple markets.

Therapeutic areas: NeurologyDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Aquestive Therapeutics

Beyond the preview

Go deeper on Otter Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otter Pharmaceuticals.

Explore the full profile